<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Frontier Medicines has raised USD 80 million in an oversubscribed Series C funding round led by Deerfield Management Company and Droia Ventures, with significant participation from Galapagos NV and others.
      </p>
    </li>
    <li>
      <p>
        The funding will be utilized to push multiple proprietary pipeline programs, including its FMC-376 candidate targeting the KRAS gene, into clinical trials.
      </p>
    </li>
    <li>
      <p>
        The company also hinted at an IPO later this year or early 2025.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.globenewswire.com/news-release/2024/02/22/2834057/0/en/Frontier-Medicines-Announces-Oversubscribed-80-Million-Series-C-Financing-to-Support-Progress-of-Clinical-Stage-Pipeline.html">
      Press release
    </a>
  </p>
  <p>
    <a href="https://www.biopharmadive.com/news/frontier-medicines-precision-cancer-kras-series-c/708272/">
      Biopharma Dive
    </a>
  </p>
  <p>
    <a href="https://bnnbreaking.com/finance-nav/business/frontier-medicines-secures-80m-in-series-c-eyes-ipo-in-bold-move-against-cancer">
      BNN Breaking
    </a>
  </p>
</div>


Precision Medicine

<div>

<p>Frontier Medicines recently procured USD 80 million in a Series C funding round that was oversubscribed. Notable participants in this round included Deerfield Management Company, Droia Ventures, Galapagos NV, and others.</p>
<p>This funding will be primarily used to progress various proprietary pipeline programs. This includes driving its FMC-376 candidate, which targets the KRAS gene, into clinical trials.</p>
<p>There has also been subtle indications from the company regarding a possible IPO, expected to occur either later this year or in early 2025.</p>

</div>

Frontier Medicines raises USD 80 million in Series C funding to develop cancer drugs; hints IPO

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 <p>Frontier Medicines has raised USD 80 million in an oversubscribed Series C funding round. The lead investors were Deerfield Management Company and Droia Ventures, while Galapagos NV and others also significantly contributed.</p>
 <p>The funding will be used to advance multiple proprietary pipeline programs into clinical trials. This includes the FMC-376 candidate, which targets the KRAS gene.</p>
 <p>Moreover, the company is considering an Initial Public Offering (IPO) later this year or at the start of 2025.</p>
 
</div>

All Updates

Frontier Medicines raises USD 80 million in Series C funding to develop cancer drugs; hints IPO

Frontier Medicines raises USD 80 million in Series C funding to develop cancer drugs; hints IPO

Frontier Medicines raises USD 88.5 million in Series B funding